Walter Kahr

Dr. Walter Kahr

orcid

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
25 March 2015 in Nature Genetics
Verified
Journal Article
Open access
PDF file
LNLeila Noetzli
Leila Noetzli
RLRichard W Lo
Richard W Lo
ALAlisa B Lee-Sherick
Alisa B Lee-Sherick
MCMichael Callaghan
Michael Callaghan
PNPatrizia Noris
Patrizia Noris
JPJorge Di Paola
Jorge Di Paola
Jorge Di Paola, Christopher Porter, Walter Kahr and colleagues report germline mutations in the transcriptional repressor gene ETV6 in three families with thrombocytopenia and elevated red blood cell volume. All three mutations affect the ability of ETV6 to repress transcription of a reporter construct, and the two protein-altering mutations affect megakaryocyte development. Some familial platelet disorders are associated with predisposition to leukemia, myelodysplastic syndrome (MDS) or dyserythropoietic anemia1,2. We identified a family with autosomal dominant thrombocytopenia, high erythrocyte mean corpuscular volume (MCV) and two occurrences of B cell–precursor acute lymphoblastic leukemia (ALL). Whole-exome sequencing identified a heterozygous single-nucleotide change in ETV6 (ets variant 6), c.641C>T, encoding a p.Pro214Leu substitution in the central domain, segregating with thrombocytopenia and elevated MCV. A screen of 23 families with similar phenotypes identified 2 with ETV6 mutations. One family also had a mutation encoding p.Pro214Leu and one individual with ALL. The other family had a c.1252A>G transition producing a p.Arg418Gly substitution in the DNA-binding domain, with alternative splicing and exon skipping. Functional characterization of these mutations showed aberrant cellular localization of mutant and endogenous ETV6, decreased transcriptional repression and altered megakaryocyte maturation. Our findings underscore a key role for ETV6 in platelet formation and leukemia predisposition.

17 July 2011 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
WKWalter Kahr
Walter Kahr
JHJesse Hinckley
Jesse Hinckley
LLLing Li
Ling Li
HSHansjörg Schwertz
Hansjörg Schwertz
HCHilary Christensen
Hilary Christensen
JPJorge Di Paola
Jorge Di Paola

3 April 2017 in Nature Communications
Verified
Journal Article
Open access
PDF file
WKWalter Kahr
Walter Kahr
FPFred G. Pluthero
Fred G. Pluthero
AEAbdul Elkadri
Abdul Elkadri
NWNeil Warner
Neil Warner
MDMarko Drobac
Marko Drobac
AMAleixo M Muise
Aleixo M Muise
Human actin-related protein 2/3 complex (Arp2/3), required for actin filament branching, has two ARPC1 component isoforms, with ARPC1B prominently expressed in blood cells. Here we show in a child with microthrombocytopenia, eosinophilia and inflammatory disease, a homozygous frameshift mutation in ARPC1B (p.Val91Trpfs*30). Platelet lysates reveal no ARPC1B protein and greatly reduced Arp2/3 complex. Missense ARPC1B mutations are identified in an unrelated patient with similar symptoms and ARPC1B deficiency. ARPC1B-deficient platelets are microthrombocytes similar to those seen in Wiskott–Aldrich syndrome that show aberrant spreading consistent with loss of Arp2/3 function. Knockout of ARPC1B in megakaryocytic cells results in decreased proplatelet formation, and as observed in platelets from patients, increased ARPC1A expression. Thus loss of ARPC1B produces a unique set of platelet abnormalities, and is associated with haematopoietic/immune symptoms affecting cell lineages where this isoform predominates. In agreement with recent experimental studies, our findings suggest that ARPC1 isoforms are not functionally interchangeable.

29 March 2021 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
LWLin Wang
Lin Wang
DADominik Aschenbrenner
Dominik Aschenbrenner
ZZZhiyang Zeng
Zhiyang Zeng
XCXiya Cao
Xiya Cao
DMDaniel Mayr
Daniel Mayr
AMAleixo M. Muise
Aleixo M. Muise

13 December 2012 in Blood
Verified
Journal Article
Open access
PDF file
DUDenisa Urban
Denisa Urban
LLLing Li
Ling Li
HCHilary Christensen
Hilary Christensen
FPFred G. Pluthero
Fred G. Pluthero
SCShao Zun Chen
Shao Zun Chen
WKWalter Kahr
Walter Kahr
Patients with platelet α or dense δ-granule defects have bleeding problems. Although several proteins are known to be required for δ-granule development, less is known about α-granule biogenesis. Our previous work showed that the BEACH protein NBEAL2 and the Sec1/Munc18 protein VPS33B are required for α-granule biogenesis. Using a yeast two-hybrid screen, mass spectrometry, coimmunoprecipitation, and bioinformatics studies, we identified VPS16B as a VPS33B-binding protein. Immunoblotting confirmed VPS16B expression in various human tissues and cells including megakaryocytes and platelets, and also in megakaryocytic Dami cells. Characterization of platelets from a patient with arthrogryposis, renal dysfunction, and cholestasis (ARC) syndrome containing mutations in C14orf133 encoding VPS16B revealed pale-appearing platelets in blood films and electron microscopy revealed a complete absence of α-granules, whereas δ-granules were observed. Soluble and membrane-bound α-granule proteins were reduced or undetectable, suggesting that both releasable and membrane-bound α-granule constituents were absent. Immunofluorescence microscopy of Dami cells stably expressing GFP-VPS16B revealed that similar to VPS33B, GFP-VPS16B colocalized with markers of the trans-Golgi network, late endosomes and α-granules. We conclude that VPS16B, similar to its binding partner VPS33B, is essential for megakaryocyte and platelet α-granule biogenesis.

2 July 2015 in Blood
Verified
Journal Article
Open access
PDF file
ABAntonija Jurak Begonja
Antonija Jurak Begonja
FPFred G. Pluthero
Fred G. Pluthero
WSWorawit Suphamungmee
Worawit Suphamungmee
SGSilvia Giannini
Silvia Giannini
HCHilary Christensen
Hilary Christensen
HFHervé Falet
Hervé Falet
Key Points: The F-BAR protein PACSIN2 associates with the initiating demarcation membrane system in megakaryocytes. FlnA binding to the PACSIN2 F-BAR domain regulates membrane tubulation in megakaryocytes, platelets, and in vitro.